home / stock / argnf / argnf quote
Last: | $469.31 |
---|---|
Change Percent: | 0.0% |
Open: | $469.31 |
Close: | $469.31 |
High: | $469.31 |
Low: | $469.31 |
Volume: | 2 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$469.31 | $469.31 | $469.31 | $469.31 | $469.31 | 2 | 07-22-2024 |
$464.5 | $464.5 | $464.5 | $464.5 | $464.5 | 50 | 07-18-2024 |
$442.89 | $442.89 | $442.89 | $453.28 | $442.89 | 15 | 07-15-2024 |
$373.5 | $0 | $373.5 | $0 | $0 | 68 | 07-11-2024 |
$373.5 | $0 | $373.5 | $0 | $0 | 10,000 | 06-27-2024 |
$373.5 | $0 | $373.5 | $0 | $0 | 20,000 | 06-24-2024 |
$373.5 | $0 | $373.5 | $0 | $0 | 129 | 06-05-2024 |
$373.5 | $0 | $373.5 | $0 | $0 | 22,000 | 05-30-2024 |
$373.5 | $0 | $373.5 | $0 | $0 | 1,000 | 05-14-2024 |
$373.5 | $373.5 | $373.5 | $373.5 | $373.5 | 11 | 05-06-2024 |
$373.501 | $373.501 | $373.501 | $373.501 | $373.501 | 116 | 05-03-2024 |
$383.74 | $0 | $383.74 | $0 | $0 | 136 | 04-18-2024 |
$383.74 | $0 | $383.74 | $0 | $0 | 48 | 03-22-2024 |
$383.74 | $383.74 | $383.74 | $383.74 | $383.74 | 100 | 03-21-2024 |
$391.775 | $391.775 | $391.775 | $391.775 | $391.775 | 1 | 02-15-2024 |
$365.68 | $365.6 | $365.68 | $365.68 | $365.6 | 16 | 02-14-2024 |
$361.93 | $0 | $361.93 | $0 | $0 | 280 | 02-09-2024 |
$361.93 | $361.93 | $361.93 | $361.93 | $361.93 | 1 | 01-11-2024 |
$371 | $0 | $371 | $0 | $0 | 97 | 01-08-2024 |
$371 | $371 | $371 | $371 | $371 | 19 | 12-25-2023 |
News, Short Squeeze, Breakout and More Instantly...
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Ju...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— ...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...